How big is TScan Therapeutics, Inc.?

As of Jun 18, TScan Therapeutics, Inc. has a market capitalization of 87.15 million, with net sales of 4.43 million and a net profit of -131.49 million over the last four quarters. The company reported shareholder's funds of 240.97 million and total assets of 371.12 million as of Dec 24.

Market Cap: As of Jun 18, TScan Therapeutics, Inc. has a market capitalization of 87.15 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, TScan Therapeutics, Inc. reported net sales of 4.43 million and a net profit of -131.49 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 240.97 million and total assets of 371.12 million.

What does TScan Therapeutics, Inc. do?

TScan Therapeutics, Inc. is a micro-cap biotechnology company focused on pharmaceuticals, reporting net sales of $2 million and a net loss of $34 million as of March 2025. Key financial metrics include a market cap of $87.15 million, a negative P/E ratio, and a return on equity of -62.03%.

Overview: <BR>TScan Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -34 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 87.15 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.02 <BR>Return on Equity: -62.03% <BR>Price to Book: 0.41<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold TScan Therapeutics, Inc.?

Is TScan Therapeutics, Inc. overvalued or undervalued?

As of November 10, 2021, TScan Therapeutics, Inc. is considered risky and overvalued due to significant losses and unfavorable valuation ratios, with a year-to-date return of -43.42%, indicating that the market may not be adequately pricing in its financial risks.

As of 10 November 2021, the valuation grade for TScan Therapeutics, Inc. moved from does not qualify to risky, indicating a heightened level of uncertainty regarding its financial health. The company appears to be overvalued given its significant losses and the valuation ratios, including a Price to Book Value of 0.48, an EV to EBIT of 0.81, and an EV to EBITDA of 0.83, which suggest that the market may not be pricing in the risks adequately. <BR><BR>In comparison to its peers, TScan's EV to EBITDA ratio of 0.83 is more favorable than Heron Therapeutics, Inc.'s -199.2793, but still lags behind TriSalus Life Sciences, Inc.'s -6.9780. The company's recent stock performance has been poor, with a year-to-date return of -43.42% compared to the S&P 500's 12.22%, reinforcing the notion that TScan is currently overvalued in the market.

Is TScan Therapeutics, Inc. technically bullish or bearish?

As of July 1, 2025, TScan Therapeutics, Inc. shows a mildly bearish trend with mixed technical indicators, including a mildly bullish weekly MACD but a bearish monthly outlook, and has significantly underperformed the S&P 500 with a year-to-date return of -43.42%.

As of 1 July 2025, the technical trend for TScan Therapeutics, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD remains bearish. The RSI shows no signal on the weekly chart but is bullish on the monthly. Bollinger Bands indicate a mildly bullish stance weekly, contrasting with a bearish monthly outlook. Moving averages are bearish on the daily timeframe, and Dow Theory reflects a mildly bearish position on both weekly and monthly charts. <BR><BR>The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -43.42% versus the S&P 500's 12.22%, and a one-year return of -68.95% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by mixed indicators across different timeframes.